Alle Studien
RekrutierungTherapeutische Bestätigung (Phase III)Interventionell

A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder

This study is testing a new medicine called Troriluzole for people who have been diagnosed with Obsessive Compulsive Disorder (OCD). It's an 'open-label' study, which means everyone involved knows they are receiving Troriluzole. The main goal is to carefully check the long-term safety of Troriluzole when it's used alongside a person's current OCD treatment. Researchers will be looking to see if there are any side effects or problems with the medicine over time. They will also check if people tolerate the medicine well and if it causes any changes in blood tests that might be important. This is a Phase 3 study, which means it’s one of the final steps before a new medicine might become available.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
Biohaven Pharmaceuticals Inc.
Einschreibeziel
43
Starten
01 Jul 2024

Worum geht es in dieser Studie?

This research study is focused on a medicine called Troriluzole for adults who have Obsessive Compulsive Disorder (OCD). OCD is a condition where people experience unwanted thoughts or fears (obsessions) and often feel the need to repeat certain actions (compulsions) to try and ease their anxiety. The study aims to understand the long-term safety of Troriluzole when it's added to a person's existing treatments for OCD.

The study is designed to be 'open-label', meaning that both the patients and the doctors know that Troriluzole is the medicine being given. This approach helps researchers gather important information about how the medicine behaves in the body over an extended period and whether it's well-tolerated by patients when used in real-world conditions.

This is called a Phase 3 study, which is a key stage in developing new medicines. At this point, researchers are usually confident that the medicine shows promise, and they are now focusing on gathering extensive information about its safety and effectiveness in a larger group of people before it can be considered for wider use.

Wichtige Erkenntnisse

  • This study is testing a new medicine, Troriluzole, for Obsessive Compulsive Disorder (OCD).
  • Its main goal is to check the long-term safety of Troriluzole when added to existing treatments.
  • It's an 'open-label' study, meaning everyone knows they are getting the medicine.
  • The study is for adults aged 18 and over, both men and women.
  • You'll have regular check-ups and follow-ups to monitor your health.

Wer könnte berechtigt sein?

To join this study, you need to be an adult, at least 18 years old. There is no upper age limit, so older adults can also take part.

Both men and women are welcome to participate in this study. The study wants to check the medicine's safety across different people.

Crucially, you must have been diagnosed with Obsessive Compulsive Disorder (OCD). The study aims to help people with this specific condition.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Have you been diagnosed with Obsessive Compulsive Disorder (OCD)?
  3. Are you currently receiving treatment for your OCD?
  4. Are you comfortable potentially taking a new medicine for a long period?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

Taking part in this study would involve regular visits to a clinic over a long period. During these visits, you would receive the study medication, Troriluzole, which you would take as prescribed. You would have various assessments, including blood tests, physical examinations, and questions about how you are feeling and any side effects you might experience. These assessments help the doctors monitor your health and how the medicine is affecting you. The total duration of your participation in the study has not been specified, but as it's a 'long-term' study, you should expect it to last for a significant period, potentially many months or even longer, with ongoing follow-up to check your health.

Potenzielle Risiken und Vorteile

Participating in this study might offer the potential benefit of trying a new medicine for your OCD that could help manage your symptoms, although this study is primarily focused on safety. However, like all medicines, Troriluzole could have side effects, and some might be serious. The researchers will be closely monitoring your health to identify any issues. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Standorte (2)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Italien
  • —
    Unbestätigt
    Spanien

Häufige Fragen

What is Troriluzole?

Troriluzole is a new medicine being studied for Obsessive Compulsive Disorder (OCD). This trial is checking its long-term safety.

What does 'open-label' mean?

It means everyone involved – you and the study doctors – knows you are receiving the active medicine, Troriluzole.

Warum ist diese Studie wichtig?

It helps researchers understand how safe Troriluzole is over a longer time when used with existing OCD treatments.

Will I still take my other OCD medicines?

Yes, Troriluzole is being studied as an 'adjunctive' treatment, meaning it’s added to your current OCD medicines.

What is 'Phase 3'?

Phase 3 is an advanced stage of testing for a new medicine, gathering a lot of safety and effectiveness information before it can be made widely available.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Multicenter, Long-Term Open-Label Safety Study of Adjuncti… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.